Sign Out
Each tablet contains: Potassium chloride, USP 750 mg (equivalent to approximately 9.8 mmol (mEq) or 393 mg K+, in sustained release formulation).
The Durules formulation provides gradual release of the active ingredient over a long period of time. By administering potassium chloride in this form, high local concentrations of the substance in the stomach or intestine are avoided. The gastrointestinal adverse effects are thereby reduced.
The plastic matrix in Potassium Chloride (Kalium Durules) is completely inert in the digestive juices but generally disintegrates under the influence of intestinal peristalsis when all active substance has been released.
Continue with Google